Claims:

1. An aqueous formulation comprising (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl 4,4,4-trifluorobutane-1-sulfonate (I) and cyclodextrin.

2. A formulation as claimed in claim 1, comprising from 0.00005 to 9.0 g/l of the compound (I) and from 0.1 to 550 g/l of cyclodextrin.

3. A formulation as claimed in either of the preceding claims, comprising from 0.0001 to 0.050 g/l of the compound (I) and from 0.2 to 200 g/l cyclodextrin.

4. A formulation as claimed in any of the preceding claims, comprising from 0.0005 to 0.025 g/l of the compound (I) and from 1 to 50 g/l cyclodextrin.

5. A formulation as claimed in any of the preceding claims, which has a pH of from 2 to 6.

6. A formulation as claimed in any of the preceding claims, comprising at least one physiologically tolerated acid.

7. A formulation as claimed in claim 6, which comprises citric acid as physiologically tolerated acid.

8. A formulation as claimed in any of the preceding claims, comprising from 8 to 10 g/l sodium chloride based on the formulation ready for use.

9. A formulation as claimed in any of the preceding claims, comprising from 0.05 to 2 g/l ethanol based on the formulation ready for use.

10. An administration kit consisting of

a) a container comprising the aqueous formulation as claimed in claims 1 to 9,

b) infusion apparatus, where at least the parts which come into contact with the product consist of polyethylene, polypropylene, polyester, polyamide, acrylonitrile-butadiene-styrene copolymers, polypropylene/ styrene-ethylene-butylene-styrene or copolymers thereof.